Gedeon Richter Chief Makes Biosimilars Prophecy
As Company Discuss Sales Prospects For Coming Quarters
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
You may also be interested in...
Gedeon Richter Pledges New Markets For Teriparatide Biosimilar
Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.
Amgen Launches Rituxan Rival In US
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
Sandoz Foresees Biosimilars Unlocking Innovation
Sandoz’ global head of biopharmaceuticals says that in the context of COVID-19, biosimilars can play a key role to increase access and unlock savings that can be invested in innovation to support “the long-term sustainability of healthcare systems.”